Pulmonary drug delivery for biologics faces significant challenges due to variability in patient breathing and inefficient lung deposition. Traditional inhalation platforms often lack precision, leading to suboptimal therapeutic outcomes. The need for targeted, reliable, and patient-friendly solutions is more urgent than ever.
This webinar introduces Kolibri™, a Non-Propellant Liquid Inhaler (NPLI) developed by Pulmotree and commercialized in partnership with Aptar Pharma. The device integrates guided inhalation and haptic feedback to optimize aerosol performance and ensure precise drug deposition. It supports both nebulizer and soft mist inhaler configurations, offering high tuneability for various formulations and patient groups.
Attendees will gain insights into how Kolibri™ enhances biologic delivery through realistic breathing profiles and in silico modeling. The presentation will also cover Aptar Pharma’s comprehensive support services—from device selection and clinical trial support to regulatory filings and patient onboarding—ensuring a streamlined development journey.
Join us to explore how Kolibri™ is revolutionizing pulmonary biologic delivery. Learn how Aptar Pharma and Pulmotree’s exclusive partnership can help you accelerate development, improve patient outcomes, and stay ahead in respiratory innovation.
Key Learning Objectives
- Understand the challenges of pulmonary drug delivery for biologics, including variability in patient breathing and the need for targeted lung deposition.
- Explore the principles of guided inhalation and haptic feedback as innovative approaches to improve aerosol performance and drug delivery precision.
- Learn how integrated device and formulation development services can accelerate clinical trials, regulatory filings, and market readiness for inhaled biologics.
- Gain insights into patient-centric design and lifecycle support strategies, including onboarding, monitoring, and human factors considerations for inhalation platforms.
